Market Cap 57.13M
Revenue (ttm) 154.90M
Net Income (ttm) -20.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -13.04%
Debt to Equity Ratio 15.74
Volume 1,571,548
Avg Vol 3,233,988
Day's Range N/A - N/A
Shares Out 189.85M
Stochastic %K 7%
Beta 1.65
Analysts Hold
Price Target $2.00

Company Profile

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed na...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 251 4400
Address:
25 Fenton Main Street, Suite 300, Cary, United States
bullishonHRTX
bullishonHRTX Aug. 20 at 2:38 PM
$HRTX I cant believe I sold my IOVA shares and bought this POS! My IOVA investment would have doubled within 3-4 weeks! What a shame!
1 · Reply
bullishonHRTX
bullishonHRTX Aug. 20 at 1:55 PM
$HRTX the Prefilled-Syringe from my speculation will bump Zyn rev to almost 100MM a year if not more. A buyer will definitely consider that in their Discounted Cash Flow (DCF)
1 · Reply
bullishonHRTX
bullishonHRTX Aug. 20 at 1:59 AM
$HRTX 650MM will easily get us over $2 per share after all covenants have been satisfied. I dont see that far fetched.
0 · Reply
bullishonHRTX
bullishonHRTX Aug. 20 at 1:55 AM
$HRTX a buyout of 650MM or more is still very in order. considering that premium can be easily amortized over 5 years, the buyer will likely be in the green in 5 years or less.
0 · Reply
bullishonHRTX
bullishonHRTX Aug. 20 at 1:53 AM
$HRTX Azurity will mostly likely not launch at risk, which means Heron's buyer at least have 12-18 months to sell Cinvanti without the competition, which can still net 100-150m. that can easily take care of Hercules covenant. The value of the NOL in a properly structured transaction is 280MM, lets say the buyer gets that at a discount of like 150-200MM. Zynrelef in prefilled syringe maybe can generate 80- 100MM a year or more in the nearest future if it gets into big pharma's hands, Aponvie is also growing. Also Big pharma can lower the price of Cinvanti even below what it cost Azurity to produce to keep the market share and make it difficult for Azurity.
2 · Reply
Tacto
Tacto Aug. 19 at 10:46 PM
$HRTX Slim pickings in that shorting pool . .
0 · Reply
slayer2408
slayer2408 Aug. 19 at 7:40 PM
$HRTX $XBI is up 7% yet we’re barely up 3% LOL
0 · Reply
ITrustno1
ITrustno1 Aug. 19 at 4:00 PM
$HRTX screw it Every $0.03 rise is 10% gain I’m going to dig in and ride this up & down for a bit with fresh cash for the swing cash in and out until it releases at a min to $0.41 again.
0 · Reply
DP000
DP000 Aug. 19 at 2:59 PM
$HRTX Anything is possible. There’s a real chance this possibility turns into something great!
0 · Reply
bullishonHRTX
bullishonHRTX Aug. 19 at 2:49 PM
$HRTX Very usually high trading volume in first hour of trading.
0 · Reply
Latest News on HRTX
Heron Therapeutics Earnings Call Transcript: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 10 days ago

Heron Therapeutics Earnings Call Transcript: Q2 2026


Heron Therapeutics Earnings release: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 10 days ago

Heron Therapeutics Earnings release: Q2 2026


Heron Therapeutics Quarterly report: Q2 2026

Aug 10, 2026, 8:30 AM EDT - 10 days ago

Heron Therapeutics Quarterly report: Q2 2026


Heron Therapeutics Transcript: AGM 2026

Jun 11, 2026, 9:00 AM EDT - 2 months ago

Heron Therapeutics Transcript: AGM 2026


Heron Therapeutics downgraded to Hold from Buy at Needham

2026-06-02T20:07:25.000Z - 2 months ago

Heron Therapeutics downgraded to Hold from Buy at Needham


Heron Therapeutics reports Q1 EPS (4c), consensus (2c)

2026-05-11T16:41:43.000Z - 3 months ago

Heron Therapeutics reports Q1 EPS (4c), consensus (2c)


Heron Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Heron Therapeutics Earnings Call Transcript: Q1 2026


Heron Therapeutics Earnings release: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Heron Therapeutics Earnings release: Q1 2026


Heron Therapeutics Quarterly report: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Heron Therapeutics Quarterly report: Q1 2026


Heron Therapeutics Slides: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Heron Therapeutics Slides: Q1 2026


Heron Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Heron Therapeutics Proxy statement: Proxy filing


Heron Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Heron Therapeutics Earnings Call Transcript: Q4 2025


Heron Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Heron Therapeutics Annual report: Q4 2025


Heron Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Heron Therapeutics Earnings release: Q4 2025


Heron Therapeutics Slides: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

Heron Therapeutics Slides: Q4 2025


Heron Therapeutics reports Q4 EPS (2c) vs 2c last year

2026-02-26T13:22:25.000Z - 6 months ago

Heron Therapeutics reports Q4 EPS (2c) vs 2c last year


Heron Therapeutics sees FY26 revenue $173M-$183M

2026-02-26T13:22:12.000Z - 6 months ago

Heron Therapeutics sees FY26 revenue $173M-$183M


Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

2026-01-09T14:35:13.000Z - 7 months ago

Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M


Heron Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Heron Therapeutics Earnings Call Transcript: Q3 2025


Heron Therapeutics Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Heron Therapeutics Quarterly report: Q3 2025


Heron Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Heron Therapeutics Earnings release: Q3 2025


Heron Therapeutics Slides: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Heron Therapeutics Slides: Q3 2025


Heron Therapeutics reports Q3 EPS (10c), consensus (1c)

2025-11-04T13:05:21.000Z - 10 months ago

Heron Therapeutics reports Q3 EPS (10c), consensus (1c)


Heron Therapeutics Proxy statement: Proxy Filing

Sep 19, 2025, 8:00 AM EDT - 11 months ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics files $125M mixed securities shelf

2025-09-09T21:15:15.000Z - 1 year ago

Heron Therapeutics files $125M mixed securities shelf


Heron Therapeutics Proxy statement: Proxy Filing

Sep 9, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics adopts tax benefits preservation plan

2025-08-15T11:50:16.000Z - 1 year ago

Heron Therapeutics adopts tax benefits preservation plan


Heron Therapeutics Earnings Call Transcript: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q2 2025


Heron Therapeutics Quarterly report: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Quarterly report: Q2 2025


Heron Therapeutics Earnings release: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Earnings release: Q2 2025


Heron Therapeutics Slides: Q2 2025

Aug 8, 2025, 8:30 AM EDT - 1 year ago

Heron Therapeutics Slides: Q2 2025


Heron Therapeutics Earnings Call Transcript: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q1 2025


Heron Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Earnings release: Q1 2025


Heron Therapeutics Quarterly report: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Quarterly report: Q1 2025


Heron Therapeutics Slides: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Slides: Q1 2025


Heron Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q4 2024


Heron Therapeutics Annual report: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Annual report: Q4 2024


Heron Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings release: Q4 2024


Heron Therapeutics Slides: Q4 2024

Feb 27, 2025, 8:00 AM EST - 1 year ago

Heron Therapeutics Slides: Q4 2024


U.S. District Court Upholds Validity of CINVANTI® Patents

Dec 3, 2024, 4:36 PM EST - 1 year ago

U.S. District Court Upholds Validity of CINVANTI® Patents


Heron Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings Call Transcript: Q3 2024


Heron Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Quarterly report: Q3 2024


Heron Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Earnings release: Q3 2024


Heron Therapeutics Slides: Q3 2024

Nov 12, 2024, 8:00 AM EST - 1 year ago

Heron Therapeutics Slides: Q3 2024


Heron Therapeutics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q2 2024


Heron Therapeutics Quarterly report: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Quarterly report: Q2 2024


Heron Therapeutics Earnings release: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings release: Q2 2024


Heron Therapeutics Slides: Q2 2024

Aug 6, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Slides: Q2 2024


Heron Therapeutics Transcript: Investor Day 2024

May 15, 2024, 9:30 AM EDT - 2 years ago

Heron Therapeutics Transcript: Investor Day 2024


Heron Therapeutics Slides: FY 2024

May 15, 2024, 9:30 AM EDT - 2 years ago

Heron Therapeutics Slides: FY 2024


Heron Therapeutics Earnings Call Transcript: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q1 2024


Heron Therapeutics Quarterly report: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Quarterly report: Q1 2024


Heron Therapeutics Earnings release: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Earnings release: Q1 2024


Heron Therapeutics Slides: Q1 2024

May 7, 2024, 8:30 AM EDT - 2 years ago

Heron Therapeutics Slides: Q1 2024


Heron Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Heron Therapeutics Proxy statement: Proxy Filing


Heron Therapeutics Earnings Call Transcript: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings Call Transcript: Q4 2023


Heron Therapeutics Annual report: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Annual report: Q4 2023


Heron Therapeutics Earnings release: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Earnings release: Q4 2023


Heron Therapeutics Slides: Q4 2023

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Heron Therapeutics Slides: Q4 2023


Heron Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Heron Therapeutics Earnings Call Transcript: Q3 2023


Heron Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Heron Therapeutics Quarterly report: Q3 2023


Heron Therapeutics Earnings release: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Heron Therapeutics Earnings release: Q3 2023


Heron Therapeutics Slides: Q3 2023

Nov 14, 2023, 4:30 PM EST - 3 years ago

Heron Therapeutics Slides: Q3 2023


Heron Therapeutics Registration statement: Registration Filing

Aug 23, 2023, 8:00 AM EDT - 3 years ago

Heron Therapeutics Registration statement: Registration Filing


Heron Therapeutics Earnings Call Transcript: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Earnings Call Transcript: Q2 2023


Heron Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Quarterly report: Q2 2023


Heron Therapeutics Earnings release: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Earnings release: Q2 2023


Heron Therapeutics Slides: Q2 2023

Aug 14, 2023, 4:30 PM EDT - 3 years ago

Heron Therapeutics Slides: Q2 2023


bullishonHRTX
bullishonHRTX Aug. 20 at 2:38 PM
$HRTX I cant believe I sold my IOVA shares and bought this POS! My IOVA investment would have doubled within 3-4 weeks! What a shame!
1 · Reply
bullishonHRTX
bullishonHRTX Aug. 20 at 1:55 PM
$HRTX the Prefilled-Syringe from my speculation will bump Zyn rev to almost 100MM a year if not more. A buyer will definitely consider that in their Discounted Cash Flow (DCF)
1 · Reply
bullishonHRTX
bullishonHRTX Aug. 20 at 1:59 AM
$HRTX 650MM will easily get us over $2 per share after all covenants have been satisfied. I dont see that far fetched.
0 · Reply
bullishonHRTX
bullishonHRTX Aug. 20 at 1:55 AM
$HRTX a buyout of 650MM or more is still very in order. considering that premium can be easily amortized over 5 years, the buyer will likely be in the green in 5 years or less.
0 · Reply
bullishonHRTX
bullishonHRTX Aug. 20 at 1:53 AM
$HRTX Azurity will mostly likely not launch at risk, which means Heron's buyer at least have 12-18 months to sell Cinvanti without the competition, which can still net 100-150m. that can easily take care of Hercules covenant. The value of the NOL in a properly structured transaction is 280MM, lets say the buyer gets that at a discount of like 150-200MM. Zynrelef in prefilled syringe maybe can generate 80- 100MM a year or more in the nearest future if it gets into big pharma's hands, Aponvie is also growing. Also Big pharma can lower the price of Cinvanti even below what it cost Azurity to produce to keep the market share and make it difficult for Azurity.
2 · Reply
Tacto
Tacto Aug. 19 at 10:46 PM
$HRTX Slim pickings in that shorting pool . .
0 · Reply
slayer2408
slayer2408 Aug. 19 at 7:40 PM
$HRTX $XBI is up 7% yet we’re barely up 3% LOL
0 · Reply
ITrustno1
ITrustno1 Aug. 19 at 4:00 PM
$HRTX screw it Every $0.03 rise is 10% gain I’m going to dig in and ride this up & down for a bit with fresh cash for the swing cash in and out until it releases at a min to $0.41 again.
0 · Reply
DP000
DP000 Aug. 19 at 2:59 PM
$HRTX Anything is possible. There’s a real chance this possibility turns into something great!
0 · Reply
bullishonHRTX
bullishonHRTX Aug. 19 at 2:49 PM
$HRTX Very usually high trading volume in first hour of trading.
0 · Reply
Highfade
Highfade Aug. 19 at 2:36 PM
$HRTX we can speculate all we want but here is the current situation and this bird ain’t flying.
0 · Reply
bullishonHRTX
bullishonHRTX Aug. 19 at 1:44 PM
$HRTX an S3 PIPE filing shows PIPE investors are expecting liquidity soon. I will be on the watch out for that.
1 · Reply
bullishonHRTX
bullishonHRTX Aug. 19 at 1:42 PM
$HRTX so let's say a deal of about 350MM is negotiated. we will have 150MM remaining for shareholders. that puts us at about 0.83 per share. except we are negotiating a good premium in the 500MM range.
1 · Reply
ReelHeel98
ReelHeel98 Aug. 19 at 1:41 PM
$HRTX does anyone think a BO gets us close to 2 bucks in SP? I have accepted I will not make miney in this long term investment but getting a little above even would be nice!
1 · Reply
bullishonHRTX
bullishonHRTX Aug. 19 at 1:40 PM
$HRTX about 150MM for Hercules, 35MM for Rubric Senior convertible, I dont know how much for PIPE investors. Then retail. safe to say about 200MM will go to debt and the rest to retail
1 · Reply
bullishonHRTX
bullishonHRTX Aug. 19 at 1:36 PM
$HRTX If there is any buyout or any deal, Hercules comes first in the order of things, then Rubric, then Velan and other participant in the private placement of about 500k shares at $15, because those ones get the exact face value of their initial investment. then other shareholders.
0 · Reply
bullishonHRTX
bullishonHRTX Aug. 19 at 1:34 PM
$HRTX The real question is, will the deal be beneficial to retail and does it maximize the NOL? was the pill extended because the NOL is an integral part of the deal?
0 · Reply
bullishonHRTX
bullishonHRTX Aug. 19 at 1:33 PM
$HRTX Hercules restructuring the debt and giving Heron a longer runway is one sign. They dont just do that most times except to give a company some kind of stability during a deal
0 · Reply
bullishonHRTX
bullishonHRTX Aug. 19 at 1:32 PM
$HRTX There are signs that can be speculated as surefire signs that a deal was on the table before the last earnings call. Whether it will be one beneficial to retail shareholders is what begs the question.
0 · Reply
Shooter40
Shooter40 Aug. 19 at 12:46 PM
$HRTX thanks for the july numbers Braddog. Zyn grew 89% and Apo grew 57% from last July. Just sayin……
1 · Reply
bullishonHRTX
bullishonHRTX Aug. 19 at 4:11 AM
$HRTX Let's watch out for any S-3 PIPE filing from Heron about the convertible notes or 8k filing from Hercules in the next 30 days
0 · Reply
Tacto
Tacto Aug. 19 at 2:50 AM
$HRTX The bad guys have only one way out, and that's to bid dollars, not pennies, for each genuine share, to the tune of many tens of millions they need to cover or settle the colossal mountain of shorts they are responsible for having poured into the float to bloat it by an unfathomable degree, to artificially dork the stock down to a microscopic fraction of what it would otherwise be Problem solved! Meanwhile, we watch and wait... . .
0 · Reply